Literature DB >> 33616876

Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease.

Kiki Waeijen-Smit1,2,3, Sarah Houben-Wilke4, Antonio DiGiandomenico5, Ulf Gehrmann6, Frits M E Franssen4,7,8.   

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of acute worsening of respiratory symptoms that require additional therapy. These events play a pivotal role in the natural course of the disease and are associated with a progressive decline in lung function, reduced health status, a low physical activity level, tremendous health care costs, and increased mortality. Although most exacerbations have an infectious origin, the underlying mechanisms are heterogeneous and specific predictors of their occurrence in individual patients are currently unknown. Accurate prediction and early diagnosis of exacerbations is essential to develop novel targets for prevention and personalized treatments to reduce the impact of these events. Several potential biomarkers have previously been studied, these however lack specificity, accuracy and do not add value to the available clinical predictors. At present, microbial composition and host-microbiome interactions in the lung are increasingly recognized for their role in affecting the susceptibility to exacerbations, and may steer towards a novel direction in the management of COPD exacerbations. This narrative review describes the current challenges and unmet needs in the management of acute exacerbations of COPD. Exacerbation triggers, biological clusters, current treatment strategies, and their limitations, previously studied biomarkers and prediction tools, the lung microbiome and its role in COPD exacerbations as well as future directions are discussed.

Entities:  

Keywords:  Biomarkers; Chronic obstructive pulmonary disease; Exacerbations; Microbiome; Microbiota

Year:  2021        PMID: 33616876      PMCID: PMC7897880          DOI: 10.1007/s11739-020-02612-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  56 in total

Review 1.  What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement.

Authors:  Victor Kim; Shawn D Aaron
Journal:  Eur Respir J       Date:  2018-11-15       Impact factor: 16.671

2.  Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease.

Authors:  Marc A Sze; Pedro A Dimitriu; Masaru Suzuki; John E McDonough; Josh D Campbell; John F Brothers; John R Erb-Downward; Gary B Huffnagle; Shizu Hayashi; W Mark Elliott; Joel Cooper; Don D Sin; Marc E Lenburg; Avrum Spira; William W Mohn; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2015-08-15       Impact factor: 21.405

3.  Symptom variability in patients with severe COPD: a pan-European cross-sectional study.

Authors:  R Kessler; M R Partridge; M Miravitlles; M Cazzola; C Vogelmeier; D Leynaud; J Ostinelli
Journal:  Eur Respir J       Date:  2010-11-29       Impact factor: 16.671

4.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease.

Authors:  D E O'Donnell; S M Revill; K A Webb
Journal:  Am J Respir Crit Care Med       Date:  2001-09-01       Impact factor: 21.405

5.  Susceptibility to exacerbation in chronic obstructive pulmonary disease.

Authors:  John R Hurst; Jørgen Vestbo; Antonio Anzueto; Nicholas Locantore; Hana Müllerova; Ruth Tal-Singer; Bruce Miller; David A Lomas; Alvar Agusti; William Macnee; Peter Calverley; Stephen Rennard; Emiel F M Wouters; Jadwiga A Wedzicha
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  Inflammatory changes, recovery and recurrence at COPD exacerbation.

Authors:  W R Perera; J R Hurst; T M A Wilkinson; R J Sapsford; H Müllerova; G C Donaldson; J A Wedzicha
Journal:  Eur Respir J       Date:  2006-11-15       Impact factor: 16.671

Review 7.  The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease.

Authors:  Gerald Burgstaller; Bettina Oehrle; Michael Gerckens; Eric S White; Herbert B Schiller; Oliver Eickelberg
Journal:  Eur Respir J       Date:  2017-07-05       Impact factor: 16.671

Review 8.  Clinical relevance of airway remodelling in airway diseases.

Authors:  A L James; S Wenzel
Journal:  Eur Respir J       Date:  2007-07       Impact factor: 16.671

9.  Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

Authors:  Jason Foo; Sarah H Landis; Joe Maskell; Yeon-Mok Oh; Thys van der Molen; MeiLan K Han; David M Mannino; Masakazu Ichinose; Yogesh Punekar
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

Review 10.  COPD exacerbations: defining their cause and prevention.

Authors:  Jadwiga A Wedzicha; Terence A R Seemungal
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

View more
  2 in total

1.  Analyzing the Treatment of Patients with Acute Exacerbation of COPD with the Aid of Intelligent Diagnosis Method.

Authors:  Qina Jiang; Guangxiang Zhao; Shiyan Song; Yujuan Chen
Journal:  J Healthc Eng       Date:  2022-03-12       Impact factor: 2.682

2.  Development and multimodal characterization of an elastase-induced emphysema mouse disease model for the COPD frequent bacterial exacerbator phenotype.

Authors:  Irene Rodríguez-Arce; Xabier Morales; Mikel Ariz; Begoña Euba; Nahikari López-López; Maider Esparza; Derek W Hood; José Leiva; Carlos Ortíz-de-Solórzano; Junkal Garmendia
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.